IgA nephropathy and inhibitors of the renin angiotensin system: Is reduction in proteinuria adequate proof of efficacy?

American Journal of Kidney Diseases

Volumn 38, Issue 1, 2001, Pages 182-185

  Reddan, Donal N ^a   Owen Jr, William F ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMMUNOGLOBULIN A; LOSARTAN; RAMIPRIL; RENIN;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; NONHUMAN; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034964360     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.26330     Document Type: Article

References (23)

1. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
2. The commonest glomerulonephritis in the world: IgA nephropathy
3. Clinical features and natural history of IgA nephropathy
4. Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
5. Primary IgA nephropathy: Natural history and factors of importance in the progression of renal impairment
6. Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses
7. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry
8. The natural history of immunoglobulin. A nephropathy among patients with hematuria and minimal proteinuria
9. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
11. Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and beta-blocking agents
12. The role of protein traffic in the progression of renal diseases
13. ACE inhibition and Ang II receptor blockade improve glomerular size-selectivity in IgA nephropathy
14. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin
15. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies
16. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
17. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
18. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine
19. Surrogate end points in clinical trials: Are we being misled?
20. Surrogate endpoints in clinical trials: Definition and operational criteria
21. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
22. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients